{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-26-000854","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2026-05-13T20:25:45+00:00","discovered_at":"2026-05-13T20:27:00.294329+00:00","generated_at":"2026-05-13T21:46:36.833240+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026","bullets":["Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).","Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.","Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.","SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.","Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-26-000854","json":"https://secwatch.observer/filing/0001753926-26-000854.json","markdown":"https://secwatch.observer/filing/0001753926-26-000854.md","text":"https://secwatch.observer/filing/0001753926-26-000854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/0001753926-26-000854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/vani-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:46:36.833240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}